Who Paid My Doc
Kwabena Ayesu
Internal Medicine Orlando, FL Medical Doctor
NPI 1225019284 CMS profile 10522
21 W Columbia St, Mp 160, Orlando, FL 32806
General payments
$1,544
Research payments
$264,195
Ownership & investment interest
$0
Research they led as principal investigator
$27,573,980
Through program year 2024, Kwabena Ayesu of Orlando, FL is reported in the CMS Open Payments database as having received $1,544 across 10 general payments and $264,195 in research payments paid to them. Separately, studies naming them as principal investigator received $27,573,980 in research payments, paid to institutions rather than to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.
General payments for this record sit in the 99th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
7 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2024 | General | $1,544 | 10 | |
| 2024 | Research | $136,555 | 1 | |
| 2023 | Research | $358 | 1 | |
| 2022 | Research | $2,695 | 1 | |
| 2021 | Research | $11,587 | 2 | |
| 2020 | Research | $78,630 | 6 | |
| 2019 | Research | $34,369 | 7 |
Beside peers
- Kwabena Ayesu
- Internal Medicine median
- Middle half of Internal Medicine
- National median
In program year 2025, general payments to Kwabena Ayesu were reported at $0. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.
Show as a table
| Year | Kwabena Ayesu | Internal Medicine median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $0 | $159 | $48–$570 | $163 |
| 2020 | $0 | $119 | $33–$402 | $114 |
| 2021 | $0 | $135 | $37–$521 | $132 |
| 2022 | $0 | $141 | $42–$496 | $149 |
| 2023 | $0 | $149 | $45–$519 | $160 |
| 2024 | $1,544 | $154 | $47–$537 | $164 |
| 2025 | $0 | $156 | $47–$551 | $169 |
Breakdown
Prescribing to Medicare patients
Part D · data year 2024 · 19 drugsPart D claims
300
Drug cost
$17,519
Branded share of claims
17%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Eliquis Apixaban | Brand | 15 | $9,959 | |
| Jardiance Empagliflozin | Brand | 11 | $6,377 | |
| Pantoprazole Sodium | Generic | 19 | $113 | |
| Nifedipine Er Nifedipine | Brand | 11 | $107 | |
| Amoxicillin-Clavulanate Potass Amoxicillin/Potassium Clav | Brand | 14 | $100 | |
| Gabapentin | Generic | 14 | $82 | |
| Losartan Potassium | Generic | 22 | $79 | |
| Amlodipine Besylate | Generic | 29 | $77 | |
| Tamsulosin Hcl | Generic | 11 | $75 | |
| Atorvastatin Calcium | Generic | 24 | $74 |
The 10 drugs with the highest cost, of 19 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.
Billing to Medicare
Part B · data year 2024 · 8 billing codesPaid by Medicare
$54,463
Medicare patients
191
Services billed
728
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 75% | |
| Ischemic heart disease | 57% | |
| Chronic kidney disease | 55% | |
| Heart failure | 52% | |
| Diabetes | 50% | |
| Depression | 47% | |
| Arthritis | 43% | |
| Atrial fibrillation | 40% |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
28 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Internal Medicine in Florida
Related records
Internal Medicine in Florida
Practitioners in the same specialty and state, ranked by reported value.
All Internal Medicine
Everyone recorded under this specialty, nationwide.
Doctors in Florida
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.